{"id":2875,"date":"2024-05-29T18:37:37","date_gmt":"2024-05-29T17:37:37","guid":{"rendered":"https:\/\/tris.sambrownprojects.com\/?p=2875"},"modified":"2024-06-01T01:48:33","modified_gmt":"2024-06-01T00:48:33","slug":"tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication","status":"publish","type":"post","link":"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/","title":{"rendered":"Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text css=&#8221;&#8221;]<\/p>\n<p style=\"text-align: center;\"><em>\u2013 ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in pediatric patients six years and older \u2013<\/em><\/p>\n<p style=\"text-align: center;\"><em>\u2013 First non-stimulant ADHD medication, with nighttime dosing, adds to Tris Pharma\u2019s established portfolio of leading ADHD therapies and reinforces company\u2019s commitment to individuals with ADHD \u2013<\/em><\/p>\n<p>MONMOUTH JUNCTION, NJ, May 29, 2024 \u2013 Business Wire \u2013 Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the U.S. Food and Drug Administration (FDA) has approved ONYDA\u2122 XR (clonidine hydrochloride), a once-a-day extended-release oral suspension with nighttime dosing, for the treatment of ADHD as a monotherapy or as an adjunctive therapy to approved central nervous system (CNS) stimulant medications in pediatric patients six years and older.<\/p>\n<p>ONYDA XR is the first non-stimulant ADHD medication in Tris\u2019 portfolio, the first-and-only liquid non-stimulant ADHD medication approved in the United States and the only approved non-stimulant ADHD medication with nighttime dosing. Non-stimulant ADHD therapies are an important option for patients who do not respond adequately to stimulant medication or experience negative side effects from them, and they are increasingly used as an effective alternative to stimulant treatments. ONYDA XR is expected to be available in pharmacies in the second half of 2024.<\/p>\n<p>\u201cPeople with ADHD require a range of therapeutic options that are designed for their individual needs, because not every medication or type of therapy works for every patient,\u201d said Ann Childress, M.D. \u00a0\u201cThe approval of ONYDA XR, the only liquid non-stimulant ADHD medication, with nighttime dosing that shifts the release profile, is a convenient option for patients needing better ADHD control.\u201d<\/p>\n<p>Tris Pharma harnessed the flexibility of its proprietary\u00a0<em>LiquiXR\u00ae<\/em>\u00a0technology to develop ONYDA XR, a liquid non-stimulant medication with a smooth, extended-release profile that physicians can use to treat ADHD patients either alone or in combination with stimulant therapy. This product adds to Tris\u2019 comprehensive and expanding portfolio of leading ADHD therapies that enhance patient care for individuals with the disorder. The company\u2019s ADHD therapies are available in both oral suspension (liquid) and solid (tablet) forms for administration to children and adults. Tris continues to grow its ADHD offerings with a pipeline of new medications that could have a substantial impact for those with the disorder.<\/p>\n<p>\u201cSecuring FDA approval for ONYDA XR is not just an important milestone, but a testament to our unwavering commitment to innovating and improving outcomes for this patient population,\u201d said Ketan Mehta, Founder and CEO at Tris Pharma. \u201cOur relentless pursuit to offer a range of ADHD medicines to patients of all ages does not stop here, and we look forward to continuing to expand our portfolio in other ADHD indications.\u201d<\/p>\n<p>The U.S. FDA approval of ONYDA XR is based on adequate and well-controlled studies of clonidine hydrochloride extended-release tablets.<\/p>\n<p><strong>About Tris Pharma<br \/>\n<\/strong>Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain, \u00a0addiction and disorders \u00a0of the central nervous system. Tris is an established commercial organization with a robust portfolio of best-in-class ADHD products and a promising pipeline of differentiated, near-term drug candidates. More information is available at\u00a0<a href=\"https:\/\/www.trispharma.com\/\"><strong>www.trispharma.com<\/strong><\/a>\u00a0and on LinkedIn @<a href=\"https:\/\/www.linkedin.com\/company\/tris-pharma\/\" target=\"_blank\" rel=\"noopener\"><strong>TrisPharma<\/strong><\/a>.<\/p>\n<p><strong>ONYDA (Clonidine hydrochloride)<\/strong><\/p>\n<p><strong>PROFESSIONAL INDICATION &amp; IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n<p><strong>INDICATION<br \/>\n<\/strong>ONYDA XR is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older.<\/p>\n<p><strong>IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n<p><strong>Contraindications:<\/strong><\/p>\n<ul>\n<li>ONYDA is contraindicated in patients with history of a hypersensitivity reaction to clonidine.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Warnings &amp; Precautions:<\/strong><\/p>\n<ul>\n<li><strong>Hypotension\/Bradycardia<\/strong>: Treatment with ONYDA XR can cause dose-related decreases in blood pressure and heart rate. Titrate slowly and monitor vital signs frequently in patients at risk for hypotension, heart block, bradycardia, syncope, cardiovascular disease, vascular disease, cerebrovascular disease, or chronic renal failure. In patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration, advise patients to avoid becoming dehydrated or overheated.<\/li>\n<li><strong>Somnolence\/Sedation<\/strong>: Somnolence and sedation were commonly reported adverse reactions in clinical studies with clonidine hydrochloride extended-release tablets. Caution patients against operating heavy equipment or driving until they know how they respond to treatment with ONYDA XR. Advise patients to avoid use with alcohol.<\/li>\n<li><strong>Cardiac Conduction Abnormalities:<\/strong>\u00a0The sympatholytic action of clonidine may worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs. There have been post-marketing reports of patients with conduction abnormalities and\/or taking other sympatholytic drugs who developed severe bradycardia requiring intravenous (IV) atropine, IV isoproterenol, and temporary cardiac pacing while taking clonidine. Titrate ONYDA XR slowly and monitor vital signs frequently in patients with cardiac conduction abnormalities or patients concomitantly treated with other sympatholytic drugs.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Adverse Reactions:<\/strong><\/p>\n<ul>\n<li>Most common adverse reactions (incidence at least 5% and twice the rate of placebo) as monotherapy in ADHD: somnolence, fatigue, irritability, nightmare, insomnia, constipation, dry mouth.<\/li>\n<li>Most common adverse reactions (incidence at least 5% and twice the rate of placebo) as adjunct therapy to psychostimulant in ADHD: somnolence, fatigue, decreased appetite, dizziness.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Drug Interactions:<\/strong><\/p>\n<ul>\n<li>CNS Depressants: Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates, or other sedating drugs. Avoid concomitant use of CNS depressants with ONYDA XR.<\/li>\n<\/ul>\n<ul>\n<li>Tricyclic Antidepressants: Concomitant use of tricyclic antidepressants with clonidine can increase blood pressure and may counteract the hypotensive effects of clonidine. Monitor blood pressure and adjust dosage of ONYDA XR as needed.<\/li>\n<li>Drugs Known to Affect Sinus Node Function or AV Nodal Conduction: Avoid use of ONYDA XR with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers and beta-blockers) due to a potential for additive effects such as bradycardia and AV block.<\/li>\n<li>Antihypertensive drugs: Concomitant use of antihypertensive drugs with clonidine potentiates the hypotensive effects of clonidine. Monitor blood pressure and heart rate and adjust dosage of ONYDA XR accordingly in patients treated concomitantly with antihypertensives.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Use in specific population:<\/strong><\/p>\n<ul>\n<li>Use in patients with renal Impairment: The impact of renal impairment on the pharmacokinetics of clonidine in pediatric patients has not been assessed. The dosage of ONYDA XR must be adjusted according to the degree of impairment, and patients should be carefully monitored.<\/li>\n<\/ul>\n<ul>\n<li>Use during pregnancy: Prolonged experience with clonidine in pregnant women over several decades, based on published literature, including controlled trials, a retrospective cohort study and case reports, have not identified a drug associated risk of major birth defects, miscarriage, and adverse maternal or fetal outcomes.<\/li>\n<\/ul>\n<p>To monitor pregnancy outcomes in women exposed to ADHD medications, including ONYDA XR, during pregnancy, healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or visiting online at\u00a0<a href=\"https:\/\/womensmentalhealth.org\/adhd-medications\/\" target=\"_blank\" rel=\"noopener\" aria-describedby=\"audioeye_new_window_message\">https:\/\/womensmentalhealth.org\/adhd-medications\/<\/a><u>.<\/u><\/p>\n<ul>\n<li>Use during lactation: The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for ONYDA XR and any potential adverse effects on the breastfed child from ONYDA XR or from the underlying maternal condition. Monitor breastfeeding infants exposed to ONYDA XR through breast milk for symptoms of hypotension and\/or bradycardia such as sedation, lethargy, tachypnea, and poor feeding.<\/li>\n<\/ul>\n<p><strong><em>\u00a0<\/em><\/strong><\/p>\n<p><strong><em>To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc. at 1-732-940-0358 or FDA at 1-800-FDA-1088 or\u00a0<\/em><\/strong><a href=\"http:\/\/www.fda.gov\/medwatch\" target=\"_blank\" rel=\"noopener\" aria-describedby=\"audioeye_new_window_message\">www.fda.gov\/medwatch<\/a><\/p>\n<p><strong>Please see\u00a0<\/strong><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217645s000lbl.pdf\" target=\"_blank\" rel=\"noopener\" aria-describedby=\"audioeye_pdf_message audioeye_new_window_message\"><strong>ONYDA PI<\/strong><\/a><strong>\u00a0for full prescribing information<\/strong><\/p>\n<p><strong>Company Contact<\/strong><\/p>\n<p>Cheryl Patnick<br \/>\nTris Pharma, Inc.<br \/>\n<a href=\"mailto:cpatnick@trispharma.com\">cpatnick@trispharma.com<\/a><\/p>\n<p><strong>Media Contact<\/strong><\/p>\n<p>Laura Morgan<br \/>\nSam Brown, Inc.<br \/>\n951.333.9110<br \/>\n<a href=\"mailto:lauramorgan@sambrown.com\">lauramorgan@sambrown.com<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text css=&#8221;&#8221;] \u2013 ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in pediatric patients six years and older \u2013 \u2013 First non-stimulant ADHD medication, with nighttime dosing, adds to Tris Pharma\u2019s established portfolio of leading ADHD therapies and reinforces company\u2019s commitment to individuals [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_wp_rev_ctl_limit":""},"categories":[25,1],"tags":[],"class_list":["post-2875","post","type-post","status-publish","format-standard","hentry","category-featured","category-uncategorised"],"acf":[],"featured_image_src":{"landsacpe":false,"list":false,"medium":false,"full":false},"yoast_head":"\n<title>Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication - Tris Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication - Tris Pharma\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text css=&#8221;&#8221;] \u2013 ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in pediatric patients six years and older \u2013 \u2013 First non-stimulant ADHD medication, with nighttime dosing, adds to Tris Pharma\u2019s established portfolio of leading ADHD therapies and reinforces company\u2019s commitment to individuals [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/\" \/>\n<meta property=\"og:site_name\" content=\"Tris Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-29T17:37:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-01T00:48:33+00:00\" \/>\n<meta name=\"author\" content=\"Jason Willis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jason Willis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/\",\"url\":\"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/\",\"name\":\"Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication - Tris Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.trispharma.com\/#website\"},\"datePublished\":\"2024-05-29T17:37:37+00:00\",\"dateModified\":\"2024-06-01T00:48:33+00:00\",\"author\":{\"@id\":\"https:\/\/www.trispharma.com\/#\/schema\/person\/d3d5bae22eb46a64de7730f650eef162\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.trispharma.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.trispharma.com\/#website\",\"url\":\"https:\/\/www.trispharma.com\/\",\"name\":\"Tris Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.trispharma.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.trispharma.com\/#\/schema\/person\/d3d5bae22eb46a64de7730f650eef162\",\"name\":\"Jason Willis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.trispharma.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/609c98426026e3bc0e00b12af22f6330?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/609c98426026e3bc0e00b12af22f6330?s=96&d=mm&r=g\",\"caption\":\"Jason Willis\"},\"url\":\"https:\/\/www.trispharma.com\/author\/jasonwillissambrown-com\/\"}]}<\/script>\n","yoast_head_json":{"title":"Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication - Tris Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/","og_locale":"en_GB","og_type":"article","og_title":"Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication - Tris Pharma","og_description":"[vc_row][vc_column][vc_column_text css=&#8221;&#8221;] \u2013 ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in pediatric patients six years and older \u2013 \u2013 First non-stimulant ADHD medication, with nighttime dosing, adds to Tris Pharma\u2019s established portfolio of leading ADHD therapies and reinforces company\u2019s commitment to individuals [&hellip;]","og_url":"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/","og_site_name":"Tris Pharma","article_published_time":"2024-05-29T17:37:37+00:00","article_modified_time":"2024-06-01T00:48:33+00:00","author":"Jason Willis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jason Willis","Estimated reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/","url":"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/","name":"Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication - Tris Pharma","isPartOf":{"@id":"https:\/\/www.trispharma.com\/#website"},"datePublished":"2024-05-29T17:37:37+00:00","dateModified":"2024-06-01T00:48:33+00:00","author":{"@id":"https:\/\/www.trispharma.com\/#\/schema\/person\/d3d5bae22eb46a64de7730f650eef162"},"breadcrumb":{"@id":"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.trispharma.com\/tris-pharma-receives-u-s-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.trispharma.com\/"},{"@type":"ListItem","position":2,"name":"Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication"}]},{"@type":"WebSite","@id":"https:\/\/www.trispharma.com\/#website","url":"https:\/\/www.trispharma.com\/","name":"Tris Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.trispharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.trispharma.com\/#\/schema\/person\/d3d5bae22eb46a64de7730f650eef162","name":"Jason Willis","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.trispharma.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/609c98426026e3bc0e00b12af22f6330?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/609c98426026e3bc0e00b12af22f6330?s=96&d=mm&r=g","caption":"Jason Willis"},"url":"https:\/\/www.trispharma.com\/author\/jasonwillissambrown-com\/"}]}},"_links":{"self":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/posts\/2875"}],"collection":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/comments?post=2875"}],"version-history":[{"count":2,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/posts\/2875\/revisions"}],"predecessor-version":[{"id":2879,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/posts\/2875\/revisions\/2879"}],"wp:attachment":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/media?parent=2875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/categories?post=2875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/tags?post=2875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}